Table 3.
Summary of polymer-drug conjugates, which are effective in vitro and in vivo against lung cancer.
| Polymer-Drug Conjugates | Carrier/Monomers Used | Drugs | Biological Outcomes | Molecular Design | Reference |
|---|---|---|---|---|---|
| Hyaluronic acid-dihydroartemisinin (HA-DHA) | Hyaluronic acid | Dihydroartemisinin | The conjugates displayed high apoptosis when compared to the free drug | The hydroxyl group of the drug was covalently linked to the carboxylic group of hyaluronic acid. | [131] |
| Hyaluronic acid-Paclitaxel (HA-PLX) | Hyaluronic acid | Paclitaxel | Significant cytotoxicity and apoptosis-inducing effect resulting from increased cellular uptake of the drug via HA-receptor mediated endocytosis. | Paclitaxel was conjugated to the C-6 position of N-acetyl-D-glucosamine of the hyaluronic acid using hexanediamine as a linker. | [132] |
| MPEG-b-norbornene functional PLA-b-P(α-BrCL) | Polylactic acid, Polyethylene glycol | Doxorubicin and paclitaxel | The incorporation of both drugs into the carrier resulted in a synergistic effect in inhibiting the proliferation of A549 cancer cells. | Both drugs were covalently incorporated into the polymer backbone | [133] |
| Polylactide-Paclitaxel (PLA-PTX) | Allyl-functionalized polylactide | Paclitaxel | Enhanced cytotoxic effect in vitro. | A polymer-drug conjugate was also obtained by thiol-ene reaction of both thiol-functionalized SB and PTX with allyl-functionalized PLA. | [134] |
| Polyethylene glycol-Paclitaxel (PEG-PTX) | Polyethylene glycol | Paclitaxel | The conjugates exhibited sustained drug release with anti-tumor activity, which was less than the free drugs. | The conjugates were prepared with either an azide linker or a succinic linker. The linear PEGs were modified with PTX at the hydroxyl. PTX was incorporated into the PEG molecule via an ester bond at the C-2′ position on the PTX side chain. | [135] |
| N-(2-hydroxypropyl)methacrylamide-Doxorubicin | N-(2-hydroxypropyl)methacrylamide | Doxorubicin | High cytotoxic activity against the lung cancer cells, which were 10-fold higher cytotoxic against B16-F10, 3LL, and HT29 cells when compared to peptide-doxorubicin. | Doxorubicin was incorporated into N-(2-hydroxypropyl)methacrylamide. | [136] |
| Poly-l-lysine-lipoic acid-Doxorubicin | Poly-l-lysine-lipoic acid | Doxorubicin | The conjugates exhibited enhanced internalization and cytotoxicity effects in vitro. It also exhibited excellent good tumor-targeting capability. | It was prepared by the modification of dimethylmaleic anhydride for enhanced cell internalization | [137] |